Stereotactic Radiation therapy in early and locally advanced inoperable renal cell carcinoma: treatment outcomes, patterns of failure and risk factors

Abstract

Abstract Introduction: Renal cell carcinomas are the most common kidney neoplasms and though they are radioresistant, ablative radiation therapy has shown a good response rate in terms of tumor eradication and a high local control rate in both primary and metastatic stages. Apart from the various other interventions available, stereotactic body radiation therapy has shown significant progress in the management of both early and metastatic renal cell cancers. There is a plethora of literature, especially in terms of retrospective studies focusing on the clinical outcomes of the use of stereotactic body radiation therapy. In the systematic review, we aim to report the clinical outcomes and identify any high-risk factors for recurrences posttreatment in both early and metastatic renal cell cancer. Methodology: We aim to perform a systematic review and meta-analysis of the available data in the last 10 years and hematological regress in and transparent manner to identify patterns of failure and high-risk factors for recurrence. The protocol has been prepared following the preferred reporting items for systematic reviews and meta-analysis (PRISMA–P) 2015 guidelines and the protocol has been registered with the international prospective registry of systematic reviews (CRD42022380543).